Products

AmCAD-UV
AmCad BioMed Corporation
Cardiology AI
AmCAD-UV is an AI-powered ultrasound software device for vascular pulsatility analysis, quantifying and classifying ultrasonic color intensity data to assist in interpreting hemodynamic variations in blood vessels. It is FDA-cleared for prescription use as a general-purpose medical image processing tool.
AmCAD-UO
AmCad BioMed Corporation
Radiology & Imaging AI
AmCAD-UO is an FDA-cleared, AI-powered ultrasound system by AmCad BioMed Corporation for the rapid, non-invasive detection and assessment of Obstructive Sleep Apnea (OSA) in awake patients.
AmCAD-UT
AmCad BioMed Corporation
Endocrinology & Metabolic AI
AmCAD-UT is an FDA-cleared AI-powered ultrasound software by AmCad BioMed Corporation for thyroid nodule detection, analysis, and TI-RADS reporting, enhancing diagnostic accuracy and streamlining workflows.

See all 3 products →

About AmCad BioMed

AmCad BioMed is a pioneering healthcare AI company specializing in advanced ultrasound solutions designed to enhance diagnostic accuracy and streamline clinical workflows. Their patented AI technologies assist physicians in the early and precise detection of various conditions by providing detailed quantification and visualization of sonographic characteristics. The company’s product portfolio includes AmCAD-UT for thyroid nodule analysis, AmCAD-UO for obstructive sleep apnea (OSA) assessment, AmCAD-UB for breast ultrasound with BI-RADS insights, and AmCAD-US for general soft tissue analysis. These FDA and CE certified devices, such as the AmCAD-UT® Detection software, analyze ultrasound images for key features like echogenic foci, echogenicity, texture, margin, and nodule size, offering objective data to support diagnostic decisions and potentially reduce indeterminate cases.

Furthermore, AmCad BioMed is advancing real-time AI integration, exemplified by their AmCAD-UT® LIVE handheld ultrasound system. This system enables physicians to immediately assess the malignancy of thyroid nodules during examinations, eliminating the need for separate image exports and significantly improving diagnostic efficiency and accuracy, which can lead to a reduction in unnecessary surgical interventions. The company is committed to addressing unmet medical needs through continuous R&D and clinical validation, expanding its focus to areas like fatty liver, liver fibrosis, and ultrasound-guided interventions for musculoskeletal therapy.

Focus Areas

Thyroid cancer detection Obstructive Sleep Apnea detection Breast ultrasound Soft tissue analysis Fatty liver Liver fibrosis Musculoskeletal therapy

Business Intelligence

Key InvestorsFann Sun Precision Co., Ltd. (strategic partner), PhytoHealth Corp. (parent company), Maywufa Healthcare Group
PartnershipsGeneva University Hospital (Switzerland), UAE (MOU), National Taiwan University Hospital's Health Management Center, China Medical University Hospital, Good Liver Clinic, Harvard Health Clinic, Sunshine Clinic, Stanford Sleep Center, Bern University Hospital
TechnologyAI-powered ultrasound imaging, Computer-Assisted Detection (CAD), patented algorithms, deep-learning, integration with Point-of-Care Ultrasound (POCUS) manufacturers
FDA Clearances4+ cleared products (estimated)

What Physicians Need to Know

Thyroid Cancer Detection (AmCAD-UT)
AmCad BioMed's AmCAD-UT is the world's first FDA-cleared and CE-certified ultrasound Computer-Assisted Detection (CAD) system for thyroid cancer. It utilizes patented AI algorithms for automated nodule recognition, quantification, and visualization of sonographic features, providing risk analysis based on global guidelines (e.g., TI-RADS, ATA, ACR). Studies indicate high accuracy, with some showing up to 100% malignant tumor detection and a 47% improvement in benign tumor detection compared to traditional methods. The system is compatible with all commercial ultrasound systems and offers real-time AI assistance, including on handheld devices.
Obstructive Sleep Apnea (OSA) Detection (AmCAD-UO)
AmCAD-UO is the world's first CE marked/FDA 510K approved ultrasound-based solution for evaluating Obstructive Sleep Apnea in awake patients. It combines a laser-guided positioning system with AI-powered CAD software to precisely scan the upper airway and analyze dynamic changes in airspace. This non-invasive, objective, and cost-effective process delivers results in approximately 10 minutes, standardizing ultrasound transducer scanning to reduce operator dependence and redefine OSA assessment.
Breast Ultrasound (AmCAD-UB)
AmCAD-UB enhances breast ultrasound scans with AI-driven BI-RADS insights for breast lesion detection and characterization. It provides real-time AI assistance, automatically detecting and outlining suspicious areas during scanning and extracting key sonographic features to generate a BI-RADS score within seconds. The system uses color-coded lesion highlights based on BI-RADS categories and can detect multiple lesions simultaneously, offering a faster, more consistent, and objective assessment, particularly beneficial for women with dense breast tissue where cancers might be missed by standard imaging.
Soft Tissue Analysis (AmCAD-US)
AmCAD-US specializes in unlocking soft tissue insights across various organs through advanced ultrasound backscatter analysis. It enhances tissue clarity by visualizing and quantifying statistical distributions of ultrasound backscattered signals. The system offers dual-mode imaging (B-mode and color-mapped ultrasound structure mode) for improved tissue state interpretation and has versatile clinical applications, including supporting liver fibrosis and pediatric hepatic steatosis assessment, aiding in early-stage diagnosis.
Fatty Liver & Liver Fibrosis
AmCad BioMed is actively involved in the real-time analysis for fatty liver (hepatic steatosis) and liver fibrosis. Their AmCAD-US solution, through ultrasound backscatter analysis, supports the assessment of liver fibrosis and pediatric hepatic steatosis. This technology aims to provide enhanced tissue clarity and quantitative insights into tissue composition, assisting in the early detection and monitoring of these liver conditions.
Musculoskeletal Therapy
AmCad BioMed is engaged in R&D and clinical validation for ultrasound-guided intervention in musculoskeletal (MSK) therapy. While specific product details are less prominent, the company's general focus on AI-powered ultrasound solutions suggests an application in providing real-time imaging for precise diagnosis, baseline assessment, monitoring of interventions, and objective tracking of progress in musculoskeletal conditions.
Physician Tip

AmCad BioMed's AI-powered ultrasound solutions are designed to seamlessly integrate into existing clinical workflows, offering physicians enhanced diagnostic accuracy and efficiency. Their systems provide objective, quantitative data and visualized sonographic features, which can significantly bolster clinical expertise and reduce inter-observer variability. The automated report generation feature streamlines documentation, freeing up valuable time. With a strong emphasis on early detection across various specialties, these tools facilitate timely interventions and contribute to improved patient outcomes. Furthermore, the compatibility with a wide range of ultrasound systems, including handheld devices, offers flexibility for diverse clinical settings and point-of-care diagnostics.

AmCad BioMed's software solutions are engineered for robust integration into standard medical imaging environments, including PACS. They demonstrate broad compatibility with various commercial ultrasound systems, ensuring flexibility for healthcare providers. The company is actively pursuing integration of its AI ultrasound technology with major international Point-of-Care Ultrasound (POCUS) manufacturers to develop handheld devices with real-time AI diagnostic capabilities. Deployment options include both cloud-based and local installations on dedicated hardware, and the systems support output in standard formats such as DICOM and PDF for efficient archiving and sharing.

Products by AmCad BioMed

3 products in the directory

AmCAD-UV
AmCad BioMed Corporation
Cardiology AI
AmCAD-UV is an AI-powered ultrasound software device for vascular pulsatility analysis, quantifying and classifying ultrasonic color intensity data to assist in interpreting hemodynamic variations in blood vessels. It is FDA-cleared for prescription use as a general-purpose medical image processing tool.
AmCAD-UO
AmCad BioMed Corporation
Radiology & Imaging AI
AmCAD-UO is an FDA-cleared, AI-powered ultrasound system by AmCad BioMed Corporation for the rapid, non-invasive detection and assessment of Obstructive Sleep Apnea (OSA) in awake patients.
AmCAD-UT
AmCad BioMed Corporation
Endocrinology & Metabolic AI
AmCAD-UT is an FDA-cleared AI-powered ultrasound software by AmCad BioMed Corporation for thyroid nodule detection, analysis, and TI-RADS reporting, enhancing diagnostic accuracy and streamlining workflows.

What the Web Says

AmCad BioMed appears to be a company with mixed reviews, particularly concerning its employer practices. While some employees found the workplace productive and the staff friendly, others reported issues with work-life balance, low pay, and job security. The company also offers a product called AmCAD-UT, an AI-assisted software for analyzing thyroid ultrasound images, which has received FDA clearance.

Overall: Mixed

Strengths

  • Productive workplace with friendly staff (reported by some employees).
  • Opportunities for advancement (reported by some employees).
  • AmCAD-UT software aids in clinical decision-making for thyroid nodule biopsy recommendations.
  • AmCAD-UT quantifies and visualizes sonographic features of thyroid nodules.
  • AmCAD-UT generates automated reports for thyroid cancer diagnosis and management.
  • AmCAD-UT uses AI contouring algorithms for defining regions of interest on ultrasound images.

Limitations

  • Poor work-life balance.
  • Low pay and benefits.
  • Lack of job security and advancement opportunities (reported by some employees).
  • Unstable work environment.
  • Allegations of forcing H1 developers to work weekends without compensation.
  • Over-hiring and then letting go of temporary employees.

Based on reviews from: Indeed.com, X-ray Interpreter (FDA Radiology AI Device), G2, Capterra

Last updated: 2026-07-17

Videos

News, demos, and interviews about AmCad BioMed.

Loading videos...

Videos load interactively. If none appear, search YouTube for AmCad BioMed →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

AmCad BioMed offers AmCAD-UT, an AI-powered ultrasound solution for thyroid nodule analysis. It provides automated nodule recognition, quantification, and visualization of sonographic features, along with risk analysis based on global guidelines. This product holds both FDA and CE certifications.
AmCAD-UO is a remote-controlled ultrasound system with Computer-Assisted Detection (CAD) software designed to evaluate OSA risk in awake patients within approximately 10 minutes. It uses laser-guided positioning to precisely scan the upper airway and analyze dynamic airspace changes, offering an objective, accurate, and cost-effective assessment. The system is FDA 510(k) cleared and CE marked, standardizing ultrasound transducer scanning to reduce operator-dependent variations.
For breast ultrasound, AmCad BioMed provides AmCAD-UB, which enhances scans with BI-RADS insights, offering real-time lesion flagging and automated report generation. For general soft tissue analysis, AmCAD-US visualizes and quantifies statistical distributions of backscattered signals from tissue compositions, providing dual-mode imaging for improved tissue state interpretation.
Yes, AmCad BioMed's AmCAD-US software supports the assessment of liver fibrosis and pediatric hepatic steatosis, commonly known as fatty liver. The company is also actively developing pioneering ultrasound AI for real-time analysis in these areas.
AmCad BioMed's flagship products, including AmCAD-UT and AmCAD-UO, hold multiple FDA and CE certifications. The company emphasizes its commitment to regulatory compliance, with several products having received FDA 510(k) clearances.
AmCAD-UT operates on a subscription-based pricing model, determined by the number of analyses or installations. While specific details on customer support and training programs are not publicly detailed, AmCad BioMed's website provides contact information for inquiries.
Founded in 2008 and listed on the Taipei Exchange in 2015, AmCad BioMed demonstrates stability, reinforced by a recent capital increase of over NTD 500 million. They are actively expanding internationally through discussions with institutions like Geneva University Hospital, an MOU with the UAE, and integrating their AI ultrasound technology with major international Point-of-Care Ultrasound (POCUS) manufacturers.

Related Companies

Clarista is a healthcare AI company that focuses on building a “trust layer” for enterprise AI, particularly within regulated industries like healthcare and financial services. The company’s platform aims to address the challenges of data fragmentation, governance, and compliance that often hinder the successful implementation of AI projects in large organizations. Clarista’s technology unifies structured […]

HelloBooks.ai is an AI-powered accounting software company that aims to automate and simplify financial management for small businesses, freelancers, and accounting professionals. The platform utilizes generative AI to handle repetitive bookkeeping tasks such as transaction categorization, receipt capture, bank reconciliation, and report generation. It is designed to reduce manual data entry and improve accuracy, allowing […]

Vero, also known as Vero.ai, is an artificial intelligence company specifically designed to augment clinical workflows and improve patient care within the healthcare sector. Their primary focus is on leveraging AI to streamline administrative tasks, enhance diagnostic accuracy, and personalize treatment plans. By automating routine processes, Vero aims to free up healthcare professionals’ time, allowing […]

Ant Group, a global digital technology provider and operator of Alipay, has significantly expanded its focus into healthcare AI. The company recently upgraded its physician platform, Haodf for Doctor, into ‘AQ for Doctor,’ an AI-powered workstation designed to support physicians across various stages of clinical practice, including online consultations, patient management, clinical decision support, and […]

e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]

PayZen is a healthcare AI company dedicated to solving the healthcare affordability crisis for both patients and providers. The company’s AI-powered platform offers personalized, interest-free, and fee-free patient financing solutions, enabling patients to manage their medical bills through affordable payment plans tailored to their unique ability to pay. This approach aims to increase access to […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.